SANARA MEDTECH INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.22 USD | -2.99% |
|
+0.89% | -31.34% |
| 17/06 | Sanara Medtech Inc. Approves Election of Robert A. Desutter to the Board | CI |
| 12/06 | Transcript : Sanara MedTech Inc. - Shareholder/Analyst Call |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 314.1 | 225.5 | 377.8 | 350.9 | 243.4 | - |
| Enterprise Value (EV) 1 | 314.1 | 225.5 | 377.8 | 350.9 | 243.4 | 243.4 |
| P/E ratio | -65.7 x | -27.4 x | -45.5 x | -79 x | -35.7 x | -257 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | 9.36 x | 8.24 x | 5.4 x | 3.15 x | 2.75 x |
| EV / Revenue | - | 9.36 x | 8.24 x | 5.4 x | 3.15 x | 2.75 x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 6,294 | 7,632 | 8,304 | 8,538 | 8,625 | - |
| Reference price 2 | 49.90 | 29.55 | 45.50 | 41.10 | 28.22 | 28.22 |
| Announcement Date | 30/03/21 | 30/03/22 | 20/03/23 | 25/03/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 24.1 | 45.84 | 64.99 | 77.3 | 88.6 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | - | -7.376 | -12.23 | -4.215 | -6.2 | -0.7 |
| Operating Margin | - | -30.61% | -26.68% | -6.49% | -8.02% | -0.79% |
| Earnings before Tax (EBT) 1 | - | -7.994 | -13.94 | -4.44 | -6.4 | -1 |
| Net income 1 | -4.356 | -8 | -7.938 | -4.303 | -6.4 | -1 |
| Net margin | - | -33.2% | -17.31% | -6.62% | -8.28% | -1.13% |
| EPS 2 | -0.7600 | -1.080 | -1.000 | -0.5200 | -0.7900 | -0.1100 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 30/03/21 | 30/03/22 | 20/03/23 | 25/03/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 6.989 | - | 9.671 | 13.04 | 15.32 | 15.52 | 15.75 | 16.02 | 17.69 | 18.54 | 19.1 | 19.5 | 20.2 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -3.412 | - | -3.194 | -3.122 | -3.012 | -1.216 | -1.866 | -0.9067 | -0.226 | -1.532 | -1.7 | -1.6 | -1.3 |
| Operating Margin | -48.83% | - | -33.03% | -23.94% | -19.66% | -7.84% | -11.85% | -5.66% | -1.28% | -8.26% | -8.9% | -8.21% | -6.44% |
| Earnings before Tax (EBT) 1 | -3.557 | - | -3.258 | -3.232 | -4.163 | -1.216 | -1.866 | -1.095 | -0.2624 | -1.799 | -1.7 | -1.7 | -1.2 |
| Net income 1 | -3.626 | -3.129 | -3.245 | -1.47 | -4.107 | -1.178 | -1.828 | -1.06 | -0.2372 | -1.764 | -1.7 | -1.7 | -1.2 |
| Net margin | -51.88% | - | -33.56% | -11.27% | -26.82% | -7.59% | -11.6% | -6.62% | -1.34% | -9.52% | -8.9% | -8.72% | -5.94% |
| EPS 2 | -0.4800 | -0.4100 | -0.4200 | -0.1800 | -0.5100 | -0.1400 | -0.2200 | -0.1300 | -0.0300 | -0.2100 | -0.2100 | -0.2000 | -0.1400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 30/03/22 | 16/05/22 | 15/08/22 | 14/11/22 | 20/03/23 | 15/05/23 | 14/08/23 | 13/11/23 | 25/03/24 | 13/05/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | 0.17 | - | - | - | - |
| Capex / Sales | - | 0.71% | - | - | - | - |
| Announcement Date | 30/03/21 | 30/03/22 | 20/03/23 | 25/03/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
28.22
USD
Average target price
44
USD
Spread / Average Target
+55.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -31.34% | 243M | |
| +55.32% | 815B | |
| +44.05% | 641B | |
| -6.75% | 352B | |
| +13.56% | 314B | |
| +10.68% | 303B | |
| +16.57% | 242B | |
| +13.31% | 218B | |
| +8.48% | 168B | |
| -2.81% | 159B |
- Stock Market
- Equities
- SMTI Stock
- Financials Sanara MedTech Inc.
